monopar therapeutics inc - MNPR
MNPR
Close Chg Chg %
72.58 -1.93 -2.66%
Closed Market
70.65
-1.93 (2.66%)
Volume: 96.75K
Last Updated:
Oct 23, 2026, 4:00 PM EDT
Company Overview: monopar therapeutics inc - MNPR
MNPR Key Data
| Open $71.84 | Day Range 69.60 - 71.84 |
| 52 Week Range 50.07 - 124.42 | Market Cap $485.63M |
| Shares Outstanding 6.71M | Public Float 3.94M |
| Beta 1.51 | Rev. Per Employee N/A |
| P/E Ratio N/A | EPS -$2.34 |
| Yield 0.00% | Dividend N/A |
| EX-DIVIDEND DATE | SHORT INTEREST N/A |
| AVERAGE VOLUME 154.58K |
MNPR Performance
| 1 Week | 1.99% | ||
| 1 Month | -17.11% | ||
| 3 Months | -35.70% | ||
| 1 Year | -13.39% | ||
| 5 Years | 208.52% |
MNPR Analyst Ratings
- Sell
- Under
- Hold
- Over
- Buy
Number of Ratings
10
Full Ratings ➔
About monopar therapeutics inc - MNPR
Monopar Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in developing proprietary therapeutics for cancer patients. It also focuses on building a drug development pipeline through the licensing, and acquisition of therapeutics in late preclinical and clinical development stages. The company was founded by Chandler Drew Robinson, Christopher M. Starr and Andrew P. Mazar in December 2014 and is headquartered in Wilmette, IL.
MNPR At a Glance
Monopar Therapeutics, Inc.
1000 Skokie Boulevard
Wilmette, Illinois 60091
| Phone | 1-847-388-0349 | Revenue | 0.00 | |
| Industry | Biotechnology | Net Income | -13,716,894.00 | |
| Sector | Health Technology | Employees | 22 | |
| Fiscal Year-end | 12 / 2026 | |||
| View SEC Filings |
MNPR Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | 3.171 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -20.576 |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | 0.00 |
MNPR Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | -623,495.182 |
| Receivables Turnover | N/A |
| Total Asset Turnover | N/A |
MNPR Liquidity
| Current Ratio | 51.353 |
| Quick Ratio | 51.353 |
| Cash Ratio | 51.33 |
MNPR Profitability
| Gross Margin | N/A |
| Operating Margin | N/A |
| Pretax Margin | N/A |
| Net Margin | N/A |
| Return on Assets | -13.648 |
| Return on Equity | -14.224 |
| Return on Total Capital | -9.941 |
| Return on Invested Capital | -14.213 |
MNPR Capital Structure
| Total Debt to Total Equity | 0.112 |
| Total Debt to Total Capital | 0.112 |
| Total Debt to Total Assets | 0.11 |
| Long-Term Debt to Equity | 0.112 |
| Long-Term Debt to Total Capital | 0.112 |
- Income Statement
- Balance Sheet
- Cash Flow Statement
Annual Financials for Monopar Therapeutics Inc - MNPR
Collapse All in section
| All values USD millions. | 2022 | 2023 | 2024 | 2025 | 5-year trend |
|---|---|---|---|---|---|
Sales/Revenue
| - | - | - | - | - |
Sales Growth
| - | - | - | - | - |
Cost of Goods Sold (COGS) incl D&A
| - | - | - | - | - |
COGS excluding D&A
| - | - | - | - | - |
Depreciation & Amortization Expense
| - | - | - | - | - |
Depreciation
| - | - | - | - | - |
Amortization of Intangibles
| - | - | - | - | - |
COGS Growth
| - | - | - | - | - |
Gross Income
| - | - | - | - | - |
Gross Income Growth
| - | - | - | - | - |
Gross Profit Margin
| - | - | - | - | - |
| 2022 | 2023 | 2024 | 2025 | 5-year trend | |
|---|---|---|---|---|---|
SG&A Expense
| 10.54M | 8.83M | 16.16M | 16.70M | |
Research & Development
| 7.59M | 5.60M | 13.01M | 9.90M | |
Other SG&A
| 2.94M | 3.23M | 3.16M | 6.80M | |
SGA Growth
| +15.44% | -16.18% | +83.01% | +3.36% | |
Other Operating Expense
| - | - | - | - | - |
Unusual Expense
| - | - | - | - | - |
EBIT after Unusual Expense
| (10.54M) | (8.83M) | (16.16M) | (16.70M) | |
Non Operating Income/Expense
| 21.24K | 429.04K | 575.30K | 2.99M | |
Non-Operating Interest Income
| 21.24K | 429.04K | 404.02K | 2.99M | |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Interest Expense
| - | - | - | - | - |
Interest Expense Growth
| - | - | - | - | - |
Gross Interest Expense
| - | - | - | - | - |
Interest Capitalized
| - | - | - | - | - |
Pretax Income
| (10.51M) | (8.40M) | (15.59M) | (13.72M) | |
Pretax Income Growth
| -15.51% | +20.09% | -85.50% | +11.99% | |
Pretax Margin
| - | - | - | - | - |
Income Tax
| - | - | - | 800 | - |
Income Tax - Current - Domestic
| - | - | - | - | - |
Income Tax - Current - Foreign
| - | - | - | - | - |
Income Tax - Deferred - Domestic
| - | - | - | - | - |
Income Tax - Deferred - Foreign
| - | - | - | - | - |
Income Tax Credits
| - | - | - | - | - |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Other After Tax Income (Expense)
| - | - | - | - | - |
Consolidated Net Income
| (10.52M) | (8.40M) | (15.59M) | (13.72M) | |
Minority Interest Expense
| - | - | - | - | - |
Net Income
| (10.52M) | (8.40M) | (15.59M) | (13.72M) | |
Net Income Growth
| -15.52% | +20.10% | -85.50% | +11.99% | |
Net Margin Growth
| - | - | - | - | - |
Extraordinaries & Discontinued Operations
| - | - | - | - | - |
Discontinued Operations
| - | - | - | - | - |
Net Income After Extraordinaries
| (10.52M) | (8.40M) | (15.59M) | (13.72M) | |
Preferred Dividends
| - | - | - | - | - |
Net Income Available to Common
| (10.52M) | (8.40M) | (15.59M) | (13.72M) | |
EPS (Basic)
| -4.1341 | -3.039 | -4.1123 | -1.8508 | |
EPS (Basic) Growth
| -13.28% | +26.49% | -35.32% | +54.99% | |
Basic Shares Outstanding
| 2.54M | 2.76M | 3.79M | 7.41M | |
EPS (Diluted)
| -4.1341 | -3.039 | -4.1123 | -1.8508 | |
EPS (Diluted) Growth
| -13.28% | +26.49% | -35.32% | +54.99% | |
Diluted Shares Outstanding
| 2.54M | 2.76M | 3.79M | 7.41M | |
EBITDA
| (10.54M) | (8.83M) | (16.16M) | (16.70M) | |
EBITDA Growth
| -15.44% | +16.18% | -83.01% | -3.36% | |
EBITDA Margin
| - | - | - | - | - |
Snapshot
| Average Recommendation | BUY | Average Target Price | 129.917 | |
| Number of Ratings | 10 | Current Quarters Estimate | -1.094 | |
| FY Report Date | 12 / 2026 | Current Year's Estimate | -2.977 | |
| Last Quarter’s Earnings | -0.71 | Median PE on CY Estimate | N/A | |
| Year Ago Earnings | -1.85 | Next Fiscal Year Estimate | -2.463 | |
| Median PE on Next FY Estimate | N/A |
Earnings Per Share
| This Quarter | Next Quarter | This Fiscal | Next Fiscal | |
|---|---|---|---|---|
| # of Estimates | 11 | 5 | 11 | 10 |
| Mean Estimate | -1.09 | -1.30 | -2.98 | -2.46 |
| High Estimates | -0.43 | -0.76 | -1.88 | 7.11 |
| Low Estimate | -2.77 | -1.59 | -5.25 | -9.07 |
| Coefficient of Variance | -75.75 | -25.28 | -40.68 | -163.21 |
Analysts Recommendations
| Current | 1 Month Ago | 3 Months Ago | |
|---|---|---|---|
| BUY | 8 | 9 | 10 |
| OVERWEIGHT | 1 | 1 | 1 |
| HOLD | 1 | 1 | 0 |
| UNDERWEIGHT | 0 | 0 | 0 |
| SELL | 0 | 0 | 0 |
| MEAN | Buy | Buy | Buy |
SEC Filings for Monopar Therapeutics Inc - MNPR
| Filing Date | Type | Category | Amended |
|---|---|---|---|
| No results | |||
Insider Actions for Monopar Therapeutics Inc - MNPR
| Date | Name | Shares | Transaction | Value |
|---|---|---|---|---|
| Oct 21, 2026 | Chandler Drew Robinson Chief Executive Officer; Director | 104,127 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $92.59 per share | 9,641,118.93 |
| Oct 6, 2026 | Christopher M. Starr Director | 13,573 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Oct 6, 2026 | Christopher M. Starr Director | 8,942 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $78.09 per share | 698,280.78 |
| Oct 6, 2026 | Christopher M. Starr Director | 5,972 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $78.82 per share | 470,713.04 |
| Oct 6, 2026 | Christopher M. Starr Director | 5,173 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $79.67 per share | 412,132.91 |
| Oct 6, 2026 | Christopher M. Starr Director | 8,400 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Oct 5, 2026 | Andrew J. Cittadine Chief Operating Officer | 59,998 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Oct 5, 2026 | Andrew J. Cittadine Chief Operating Officer | 58,054 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $79.67 per share | 4,625,162.18 |
| Oct 5, 2026 | Andrew J. Cittadine Chief Operating Officer | 35,115 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Oct 5, 2026 | Chandler Drew Robinson Chief Executive Officer; Director | 104,724 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $79.67 per share | 8,343,361.08 |
| Oct 5, 2026 | Chandler Drew Robinson Chief Executive Officer; Director | 83,602 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Oct 5, 2026 | Quan Anh Vu Chief Financial Officer | 2,835 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Oct 5, 2026 | Quan Anh Vu Chief Financial Officer | 2,655 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $79.67 per share | 211,523.85 |
| Oct 5, 2026 | Quan Anh Vu Chief Financial Officer | 7,984 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Dec 18, 2025 | Arthur J. Klausner Director | 13,883 | Other acquisition or disposition | 0.00 |
| Dec 18, 2025 | Gem Pharmaceuticals LLC | 567,580 | Other acquisition or disposition | 0.00 |